Asset Details
Do you wish to reserve the book?
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
Do you wish to request the book?
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
2009
Overview
Objective:To perform a systematic literature review of the long-term safety of methotrexate (MTX) monotherapy in rheumatoid arthritis (RA).Methods:A search was performed in Medline, Cochrane and EMBASE. Adults with RA who had received MTX monotherapy for more than 2 years were studied.Results:88 published studies were included. Over 12 years of treatment, the termination rate of MTX due to toxicity was less than for sulfasalazine, gold, d-penicillamine and higher than for hydroxychloroquine (level of evidence 2a–2b). Long-term use of MTX does not appear to be a risk factor for serious infections, including herpes zoster (2b–4), and could provide a survival benefit by reducing cardiovascular mortality (2b). The prevalence of raised liver enzymes (more than twice the upper limit of normal) is close to 13% of patients; 3.7% of patients stopped MTX permanently owing to liver toxicity (2b). Data on the risk for liver fibrosis/cirrhosis are conflicting: a meta-analysis showed an incidence of fibrosis of 2.7% after 4 years of MTX (2a). However, two other studies on sequential liver biopsies did not show evidence for developing severe damage (2b). Insufficient data are available to fully assess the risk of lymphoma and malignancies, although there is no strong evidence of increased risk (2b–4).Conclusion:This systematic literature search on MTX monotherapy with relatively low-dose use during at least 2 years shows favourable long-term safety.
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism,BMJ Publishing Group,Elsevier Limited
Subject
/ Antirheumatic Agents - administration & dosage
/ Antirheumatic Agents - adverse effects
/ Arthritis, Rheumatoid - drug therapy
/ Arthritis, Rheumatoid - mortality
/ Biological and medical sciences
/ Bones, joints and connective tissue. Antiinflammatory agents
/ Cardiovascular Diseases - chemically induced
/ Chemical and Drug Induced Liver Injury
/ Clinical and Epidemiological Research
/ Diseases of the osteoarticular system
/ Humans
/ Infections - chemically induced
/ Liver
/ Methotrexate - administration & dosage
/ Methotrexate - adverse effects
/ Neoplasms - chemically induced
/ Pharmacology. Drug treatments
/ Pneumonia - chemically induced
/ Toxicity
/ Ulcers
